← Browse by Condition

Medical Condition

glioblastoma

Total Trials

27

Recruiting Now

27

Trial Phases

Phase 2, Phase 1, EARLY_Phase 1

ClinicalMetric tracks all active clinical trials for glioblastoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — glioblastoma Clinical Trials

How many clinical trials are currently recruiting for glioblastoma?

ClinicalMetric currently tracks 27 actively recruiting clinical trials for glioblastoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 27. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for glioblastoma?

glioblastoma research spans Phase 1 (10 trials), Phase 2 (10 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a glioblastoma clinical trial?

Eligibility criteria for glioblastoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

10

Phase 2

10

Top Sponsors

Jasper Gerritsen 2 trials

Medical University of Warsaw 2 trials

Case Comprehensive Cancer Center 2 trials

Washington University School of Medicine 2 trials

Jules Bordet Institute 1 trial

Recruiting Clinical Trials

The SAFE-Trial: Awake Craniotomy Versus Surgery Under General Anesthesia for Glioblastoma Patients.

Belgium, Netherlands

Jasper Gerritsen

Molecular Imaging of Cancer-associated Fibroblasts in Glioblastoma: a FAPI PET/MR Study.

Jules Bordet Institute

Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) In Newly Diagnosed Glioma (WHO G3-G4)

Medical University of Warsaw

NCT07003542 Phase 2

A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas

Case Comprehensive Cancer Cent...

Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma

Washington University School o...

NCT07551336 Phase 1

Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma

Beijing Biotech

NCT06613841 EARLY_Phase 1

Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma

Abramson Cancer Center at Penn...

NCT05698524 Phase 1

A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma

University of Nebraska

Serial MRI Scans During Radiation Therapy

Dana-Farber Cancer Institute

NCT07670026 Phase 2

Intensified Adjuvant Therapy for High-Risk Newly Diagnosed Glioblastoma With Subtotal Resection or Short-Term Progression

Second Affiliated Hospital, Zh...

NCT05653635 Phase 2

Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study

Centre Paul Strauss

The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma

United States, Belgi...

Erasmus Medical Center

NCT05565118 Phase 1

Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression

Case Comprehensive Cancer Cent...

The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)

United States, Belgi...

Jasper Gerritsen

NCT05683808 Phase 2

Venous Thromboembolism Prevention in Outpatients With Glioma

University of Vermont Medical ...

NCT07464925 Phase 1

A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma

Tetragon Biosciences Ltd

NCT07476794 Phase 2

Daily Temozolomide for Elderly Patients With Unmethylated MGMT- Promoter Newly Diagnosed GliOblatoma

Sunnybrook Health Sciences Cen...

NCT05590689 Phase 1, Phase 2

Radiodynamic Therapy (RDT) With Gliolan in Patients With First Recurrence of Brain Tumor

Universität Münster

Hypofractionated Radiotherapy

The First Hospital of Jilin Un...

NCT07089641 Phase 1

ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial

Jonsson Comprehensive Cancer C...

NCT07356973 Phase 2

Irinotecan-ChemoSeed in Surgically Resectable Glioblastoma

CRISM Therapeutics LTD

Extensive Resection of Malignant Brain Tumors Using Advanced Imaging Techniques

Amsterdam UMC, location VUmc

NCT06640582 Phase 1, Phase 2

TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas

Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)

Northwell Health

NCT05768919 Phase 1, Phase 2

Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas

SignPath Pharma, Inc.

NCT07392957 Phase 1, Phase 2

Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma

Washington University School o...

Analysis of Cerebrospinal Fluid Leakage After Surgery for Intracranial Tumors

Medical University of Warsaw

Related Conditions

glioblastoma multiforme of brain (5) glioma (4) glioblastoma multiforme (3) brain tumor (3) brain cancer (3) brain neoplasms (3) recurrent glioblastoma (3) glioblastoma idh wildtype (3) high grade glioma (3) astrocytoma grade iv (2) gliosarcoma (2) astrocytoma malignant (2)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology